Topoisomerases in human leukemia. (Q41315133)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8996600%20AND%20SRC:MED&resulttype=core&format=json

22 October 2019

review article

1 reference

title

Topoisomerases in human leukemia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8996600%20AND%20SRC:MED&resulttype=core&format=json

22 October 2019

Topoisomerases in Human Leukemia (English)

0 references

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8996600%20AND%20SRC:MED&resulttype=core&format=json

22 October 2019

author name string

Peereboom D

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8996600%20AND%20SRC:MED&resulttype=core&format=json

22 October 2019

Charron M

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8996600%20AND%20SRC:MED&resulttype=core&format=json

22 October 2019

David Peereboom

1

0 references

Martin Charron

2

0 references

Scott H. Kaufmann

3

0 references

publication date

1 January 1994

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8996600%20AND%20SRC:MED&resulttype=core&format=json

22 October 2019

1994

0 references

published in

Advances in Pharmacology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8996600%20AND%20SRC:MED&resulttype=core&format=json

22 October 2019

volume

29B

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8996600%20AND%20SRC:MED&resulttype=core&format=json

22 October 2019

page(s)

33-50

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8996600%20AND%20SRC:MED&resulttype=core&format=json

Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I.

22 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961130-8

7 January 2021

Etoposide (VP-16-213)-induced gene alterations: potential contribution to cell death

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961130-8

7 January 2021

Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961130-8

7 January 2021

Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961130-8

7 January 2021

Characterization and immunological identification of cDNA clones encoding two human DNA topoisomerase II isozymes

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961130-8

7 January 2021

Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961130-8

7 January 2021

Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961130-8

7 January 2021

Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961130-8

7 January 2021

Does bulk damage to DNA explain the cytostatic and cytotoxic effects of topoisomerase II inhibitors?

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961130-8

7 January 2021

Biochemistry of multidrug resistance mediated by the multidrug transporter

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961130-8

7 January 2021

Teniposide in the treatment of leukemia: a case study of conflicting priorities in the development of drugs for fatal diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961130-8

7 January 2021

Mitoxantrone resistance in HL-60 leukemia cells: reduced nuclear topoisomerase II catalytic activity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase II beta isoform

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961130-8

7 January 2021

Increased P-glycoprotein expression and multidrug-resistant gene (mdr1) amplification are infrequently found in fresh acute leukemia cells. Sequential analysis of 15 cases at initial presentation and relapsed stage

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961130-8

7 January 2021

m-AMSA as a probe for transport phenomena associated with anthracycline resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961130-8

7 January 2021

Two independent amsacrine-resistant human myeloid leukemia cell lines share an identical point mutation in the 170 kDa form of human topoisomerase II

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961130-8

7 January 2021

An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961130-8

7 January 2021

Biochemical basis for the interactions of type I and type II topoisomerases with DNA.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961130-8

7 January 2021

Novel selection and genetic characterisation of an etoposide-resistant human leukaemic CCRF-CEM cell line

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961130-8

7 January 2021

Localization of DNA topoisomerase II in Chinese hamster fibroblasts by confocal and electron microscopy

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961130-8

7 January 2021

Some reasons for the lack of progress in the treatment of acute myelogenous leukemia: a review of three consecutive trials of the treatment of poor prognosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961130-8

7 January 2021

Topoisomerase-II activity in human leukemic and lymphoblastoid cells

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961130-8

7 January 2021

Cellular and pharmacologic aspects of drug resistance in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961130-8

7 January 2021

Etoposide in leukemia, lymphoma and bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961130-8

7 January 2021

Molecular cloning of a cDNA of a camptothecin-resistant human DNA topoisomerase I and identification of mutation sites

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961130-8

7 January 2021

DNA topoisomerase activities in concanavalin A-stimulated lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961130-8

7 January 2021

Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961130-8

7 January 2021

Long chemotherapy-free remissions after single-cycle timed-sequential chemotherapy for acute myelocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961130-8

7 January 2021

The 180-kDa isoform of topoisomerase II is localized in the nucleolus and belongs to the structural elements of the nucleolar remnant

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2961130-8

7 January 2021

10.1016/S1054-3589(08)61130-8

Identifiers

DOI

0 references

1 reference